Loading
Vertex Pharmaceuticals INC / MA Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 07 Aug 2025.
Vertex Pharmaceuticals INC / MA: what insiders have been doing
Vertex Pharmaceuticals INC / MA, classified in the Healthcare & Pharma sector, is a listed company based in Boston, United States, founded in 1989. Its insiders report their share dealings to SEC (Form 4). 22 insiders have disclosed 92 filings since 18 October 2025.
All open-market trades in the period are sales: 21 sales worth €17.6M, by 10 insiders, with no purchase on record. The totals exclude 3 filings filed without an amount. At €2.7M, the sale published on 5 December 2025 by Wagner Charles F Jr is the largest of the period.
Compared with its exchange (5,458 companies, median 22 filings), a count of 92 filings is above the norm. Over the whole record (from 2016), the tally stands at 4 purchases and 209 sales. In its latest annual report filed with the SEC (10-K, fiscal year ended 31 December 2025), the company reported revenue of 12.00 bn USD and net income of 3.95 bn USD.
Filings reach the SEC (Form 4) feed a median of 2 days after the trade. The legal deadline for a Form 4 is two business days after the transaction. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives.
For comparison within the same sector, see the insider buying recorded at Anixa Biosciences Inc and Vivos Inc. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
570
Thresholds
n/a
Buy Volume
€5M
4 ops. · all time
Sell Volume
€143M
209 ops. · all time
Who traded when
BuySaleCarmen Bozic9 sales
Altshuler David6 sales
Ourania Tatsis4 sales
Kewalramani Reshma1 buy2 sales
Wagner Charles F Jr3 sales
Bhatia Sangeeta N.2 sales
+6 other insiders
Since the insiders bought
- +42.9%Entry US$366.54 · Close at T+365 US$523.91
- +42.9%Entry US$366.54 · Close at T+365 US$523.91
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Vertex Pharmaceuticals INC / MA Buy (bullish), based on 28 analysts. Average price target: US$571.39.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 6,046 of 24,148 companies
64.1
score / 100
Value39
Quality89
FCF yld2.4%
Earn yld3.0%
EV/EBITDA27.9x
ROE24%
Gross mgn86%
Net mgn33%
Debt/EBITDA0.4x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$527.67
Analyst consensus
28 analystsBuy
US$350.00Target US$571.39(+8%)US$672.00
Income statement
RevenueUS$12B
Gross profitUS$10.4B86% margin
EBITDAUS$4.9B41% margin
Net incomeUS$4B35.0% margin
Valuation
PER (trailing)30.7x
PER (forward)26.2x
P/Book6.6x
Beta0.32
Balance sheet & cash
Market capUS$133.7B
Total debtUS$2B
Free Cash FlowUS$3.2B
Debt / Equity10%
Profitability & ownership
ROE23.5%
ROA11.9%
% insiders0.2%
% institutions98.0%
Last declaration on 10 September 2026
Declarations570 total
8,682 shares0Common StockSEC:0000875320-26-000272:0
5,000 shares0Common StockSEC:0000875320-26-000267:0
6,000 shares0Common StockSEC:0000875320-26-000261:0
1,210 shares@ US$547.55100.0% of flowCommonSEC144:0001958244-26-000559
8,251 shares0Common StockSEC:0000875320-26-000251:0
8,251 shares0Common StockSEC:0000875320-26-000253:0
1,541 shares@ US$519.000.0006% mcap15.3% of flowCommonSEC144:0001959173-26-005057
1,500 shares@ US$524.990.0006% mcap9.4% of flowCommonSEC144:0001959173-26-005073
596 sharesCommon StockSEC:0000875320-26-000239:0
596 shares@ US$482.500.0002% mcap3.2% of flowCommonSEC144:0001959173-26-004906
1,020 sharesCommon StockSEC:0000875320-26-000237:0
1,020 shares@ US$462.170.0004% mcap5.2% of flowCommonSEC144:0001959173-26-004764
4,062 sharesCommon StockSEC:0000875320-26-000235:0
4,062 shares@ US$450.000.0015% mcap20.1% of flowCommonSEC144:0001959173-26-004654
1,745 shares@ US$450.000.0005% mcap1.9% of flowCommon StockSEC:0000875320-26-000233:0
1,745 shares@ US$450.000.0006% mcap8.6% of flowCommonSEC144:0001959173-26-004391
1,974 shares@ US$450.000.0007% mcap2.1% of flowCommon StockSEC:0000875320-26-000228:0
6,988 shares@ US$450.000.0024% mcap7.4% of flowCommon StockSEC:0000875320-26-000222:0
2,329 shares@ US$450.950.0008% mcap2.5% of flowCommon StockSEC:0000875320-26-000149:0
2,329 shares@ US$481.7912.4% of flowCommon StockSEC:0000875320-26-000140:0
2,633 shares@ US$498.4224.7% of flowCommon StockSEC:0000875320-26-000138:0
2,437 shares@ US$475.3021.8% of flowCommon StockSEC:0000875320-26-000136:0
25 of 570 declarations
About Vertex Pharmaceuticals INC / MA
Vertex Pharmaceuticals Incorporated is a U.S. biopharmaceutical company listed on the NASDAQ under the ticker VRTX, headquartered in the United States in Boston, Massachusetts. Founded in 1989, the company was built on a science-driven drug discovery model centered on rational design and structural biology. Over time, Vertex evolved from a highly focused research organization into a diversified specialty pharmaceutical group. For French-speaking investors in Europe, it is best viewed as a high-quality healthcare name with strong scientific credentials, a durable competitive moat, and exposure to diseases with significant unmet medical need.
Vertex’s core business has historically been cystic fibrosis (CF), where it established a near-dominant market position through a portfolio of CFTR modulators. These therapies have materially changed the treatment landscape and still represent the company’s main commercial engine. More recently, Vertex has broadened its platform beyond CF, building a second growth pillar in gene editing and serious hematology, including Casgevy in certain sickle-cell disease and transfusion-dependent beta-thalassemia settings, and expanding into pain management with Journavx (suzetrigine), an important strategic move that reduces dependence on the CF franchise. The pipeline also includes additional programs in pain, kidney disease, and other genetic disorders.
Read moreShow less
From a competitive standpoint, Vertex stands out for the depth of its scientific expertise, the strength of its intellectual property position, and the high barriers to entry in its core franchises. Its CF business remains one of the most profitable and defensible franchises in specialty pharma, supported by years of clinical leadership and close engagement with physicians and patient groups. Geographically, the company has a global footprint, with research, development, and commercial operations concentrated in the United States and Europe, and commercial reach extending into multiple international markets. This makes Vertex a globally relevant biopharma company rather than a purely domestic U.S. story.
Recent highlights have centered on the commercialization of new therapies, continued pipeline expansion beyond CF, and ongoing regulatory and launch execution for next-generation products. For investors, that means the story is no longer only about protecting the legacy CF franchise; it is also about whether Vertex can successfully convert its scientific platform into a broader multi-product growth company. The investment case therefore combines visibility from an established blockbuster franchise with upside tied to pipeline execution, label expansion, and the scaling of newer launches in the United States and abroad.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
